Published in Blood on October 01, 1993
Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci U S A (1997) 3.08
Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood (1999) 2.66
Clinical and experimental applications of sodium phenylbutyrate. Drugs R D (2011) 1.32
Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood (2002) 1.26
Phenylbutyrate induces antimicrobial peptide expression. Antimicrob Agents Chemother (2009) 1.21
Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood (2001) 1.19
BP1, a homeodomain-containing isoform of DLX4, represses the beta-globin gene. Mol Cell Biol (2002) 1.15
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs (2006) 1.05
Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica (2012) 0.91
Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease. Blood Cells Mol Dis (2009) 0.91
Radioprotection by the histone deacetylase inhibitor phenylbutyrate. Radiat Environ Biophys (2011) 0.87
A combined approach for β-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) induction. Ann Hematol (2012) 0.86
Identification of Id2 as a globin regulatory protein by representational difference analysis of K562 cells induced to express gamma-globin with a fungal compound. Mol Cell Biol (1999) 0.83
Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders. Int J Hematol Oncol Stem Cell Res (2013) 0.82
Evaluation of Signaling Pathways Involved in γ-Globin Gene Induction Using Fetal Hemoglobin Inducer Drugs. Int J Hematol Oncol Stem Cell Res (2013) 0.75
Hemoglobin switching in humans is accompanied by changes in the ratio of the transcription factors, GATA-1 and SP1. Mol Med (1995) 0.75
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res (1994) 1.86
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82
Proliferation and maturation of human erythroid progenitors in liquid culture. Blood (1989) 1.78
Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med (1988) 1.56
Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol Cell Biol (1995) 1.45
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res (1994) 1.39
Pathophysiology of sickle cell disease: role of cellular and genetic modifiers. Semin Hematol (2001) 1.38
Novel 6,7-diphenyl-2,3,8,8a-tetrahydro-1H-indolizin-5-one analogues as cytotoxic agents. Bioorg Med Chem Lett (2003) 1.35
Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res (1993) 1.34
Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (1995) 1.33
Periodic microcirculatory flow in patients with sickle-cell disease. N Engl J Med (1984) 1.32
Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene. Biochem Biophys Res Commun (1984) 1.29
Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. Blood (1996) 1.26
Percutaneous transluminal in vivo gene transfer by recombinant adenovirus in normal porcine coronary arteries, atherosclerotic arteries, and two models of coronary restenosis. Circulation (1994) 1.23
Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore) (2001) 1.23
Expression of hGC-1 is correlated with differentiation of gastric carcinoma. Histopathology (2007) 1.19
Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest (1999) 1.15
Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci U S A (1993) 1.12
Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia (1999) 1.05
Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin. Blood (1995) 1.02
Two-phase liquid culture system models normal human adult erythropoiesis at the molecular level. Eur J Haematol (2000) 1.02
Sickle cell anemia--basic research reaches the clinic. N Engl J Med (1995) 1.01
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori (1998) 0.99
Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med (1992) 0.98
Novel indolo[2,1-b]quinazoline analogues as cytostatic agents: synthesis, biological evaluation and structure-activity relationship. Bioorg Med Chem Lett (2002) 0.98
Cell heterogeneity in sickle cell disease: quantitation of the erythrocyte density profile. J Lab Clin Med (1985) 0.97
The two-step liquid culture: a novel procedure for studying maturation of human normal and pathological erythroid precursors. Stem Cells (1993) 0.97
Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol (1997) 0.96
Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. Blood (1993) 0.95
Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer (1993) 0.94
Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. Lancet (2000) 0.94
Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem (1996) 0.92
Identification of upstream regulatory elements that repress expression of adult beta-like globin genes in a primitive erythroid environment. Blood Cells Mol Dis (1998) 0.92
Restoration of the CCAAT box or insertion of the CACCC motif activates [corrected] delta-globin gene expression. Blood (1997) 0.92
Interferon-induced revertants of ras-transformed cells: resistance to transformation by specific oncogenes and retransformation by 5-azacytidine. Mol Cell Biol (1987) 0.91
Intracellular polymerization. Disease severity and therapeutic predictions. Ann N Y Acad Sci (1989) 0.90
Development of transformed phenotype induced by a human ras oncogene is inhibited by interferon. Biochem Biophys Res Commun (1985) 0.90
Prospective identification of erythroid elements in cultured peripheral blood. Exp Hematol (1999) 0.89
The role of trans-acting factors and DNA-bending in the silencing of human beta-globin gene expression. Nucleic Acids Res (2000) 0.88
Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia. Hemoglobin (2001) 0.88
Cinnamic acid: a natural product with potential use in cancer intervention. Int J Cancer (1995) 0.88
Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res (1997) 0.88
Sickle cell disease pathophysiology. Baillieres Clin Haematol (1993) 0.88
Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis. Br J Haematol (1995) 0.87
Inhibition of estrogen-dependent breast cell responses with phenylacetate. Int J Cancer (2001) 0.87
RNA transcripts of the beta-thalassaemia allele IVS-2-654 C-->T: a small amount of normally processed beta-globin mRNA is still produced from the mutant gene. Br J Haematol (1994) 0.87
Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood (1992) 0.86
Sickling of nucleated erythroid precursors from patients with sickle cell anemia. Exp Hematol (1998) 0.86
Sickle cell rheology is determined by polymer fraction--not cell morphology. Am J Hematol (1995) 0.86
Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol (1996) 0.86
Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int J Cancer (1995) 0.86
Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Dermatol (1994) 0.85
Growth of human normal erythroid progenitors in liquid culture: a comparison with colony growth in semisolid culture. Int J Cell Cloning (1991) 0.85
Comparison of three porcine restenosis models: the relative importance of hypercholesterolemia, endothelial abrasion, and stenting. Coron Artery Dis (1994) 0.85
Hydroxyurea induces a senescence-like change of K562 human erythroleukemia cell. J Cancer Res Clin Oncol (2000) 0.85
Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacol (1996) 0.84
Identification in Tetrahymena pyriformis of 3-hydroxy-3-methyl glutaryl coenzyme a lyase: its purification and properties. Int J Biochem (1987) 0.83
Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin Cancer Res (1996) 0.83
Contributions of sickle hemoglobin polymer and sickle cell membranes to impaired filterability. Am J Physiol (1995) 0.83
Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies. Curr Top Microbiol Immunol (1995) 0.82
Red blood cell glucose-6-phosphate dehydrogenase activity in aged humans. J Am Geriatr Soc (1983) 0.82
Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol (1995) 0.82
Posttranscriptional down-regulation of ras oncogene expression by inhibitors of cellular glutathione. Mol Cell Biol (1993) 0.81
Irreversibly sickled erythrocytes in sickle cell anemia: a quantitative reappraisal. Am J Hematol (1985) 0.81
Conjunctival sign in sickle cell anaemia: an in-vivo correlate of the extent of red cell heterogeneity. Br J Ophthalmol (1985) 0.81
The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. Prostate (1996) 0.81
Effect of nitric oxide and nitric oxide donors on red blood cell oxygen transport. Br J Haematol (2000) 0.81
Phenylbutyrate induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells. Clin Cancer Res (1999) 0.81
Activation of the human delta-globin gene promoter in primary adult erythroid cells. Br J Haematol (1998) 0.81
Phenylacetate in chemoprevention: in vitro and in vivo suppression of 5-aza-2'-deoxycytidine-induced carcinogenesis. Clin Cancer Res (1995) 0.81
Hb Seal Rock [(alpha 2)142 term-->Glu, codon 142 TAA-->GAA]: an extended alpha chain variant associated with anemia, microcytosis, and alpha-thalassemia-2 (-3.7 Kb). Hemoglobin (1997) 0.80
Transcriptional inhibition of Ha-ras in interferon-induced revertants of ras-transformed mouse cells. Cancer Res (1988) 0.80
Cytostatic activity of phenylacetate and derivatives against tumor cells. Correlation with lipophilicity and inhibition of protein prenylation. Biochem Pharmacol (1995) 0.79
Nitric oxide transport on sickle cell hemoglobin: where does it bind? Free Radic Res (2001) 0.79
Differences in radiation-induced micronuclei yields of human cells: influence of ras gene expression and protein localization. Int J Radiat Biol (1993) 0.79
Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells. Cytokine (1995) 0.79
Thrombopoietin has a differentiative effect on late-stage human erythropoiesis. Br J Haematol (1999) 0.79
Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate. J Neurosurg (1995) 0.79
Cryoprecipitate therapy in amniotic fluid embolization. Am J Med (1984) 0.79
Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate. Int J Radiat Biol (1997) 0.79
A two-step liquid culture--a novel culture procedure for studying erythroid cell development. Haematologia (Budap) (1991) 0.78
Biological and morphological characteristics of phenotypic revertants appearing in interferon-treated mouse cells transformed by a human oncogene. J Exp Pathol (1985) 0.78
Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study. Am J Hematol (2001) 0.78
Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression. Sci China B (1994) 0.78
Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Int J Cancer (1995) 0.78
Hydroxyurea in sickle cell disease. N Engl J Med (1996) 0.78
Alpha thalassemia changes erythrocyte heterogeneity in sickle cell disease. J Clin Invest (1985) 0.78
Monoclonal antibody-based methods for quantitation of hemoglobins: application to evaluating patients with sickle cell anemia treated with hydroxyurea. Eur J Haematol (1996) 0.78
Flow cytofluorometric analysis of the uptake of the fluorescent fatty acid pyrene-dodecanoic acid by human peripheral blood cells. Cytometry (1988) 0.78